Pharmaceutical manufacturers whose products participate in government drug pricing programs must navigate an ever-evolving legislative landscape to strike a balance between risk and value. One program in particular – the 340B Drug Pricing Program – poses a significant risk of revenue loss thanks to the complicated issue of duplicate discounts. 

What are duplicate discounts?  

Also known as “double dipping,” duplicate discounts occur when a manufacturer is asked to provide both a 340B discount and a Medicaid rebate for the same drug. This situation is prohibited under 340B program regulations and failure to comply can be profoundly costly in terms of fines, remediation costs, and reputational damage.  

Topics covered will include:  

• How and why double dipping occurs 
• The impact double dipping can have on your business 
• What Model N 340B Vigilance does to help you protect revenue and reduce the risk associated with double dipping 
• How real Model N clients are leveraging the module to prevent overpayments 

Watch our webinar for expert insight into the causes of – and solutions for – duplicate discounts under the 340B program. 

Featured Speakers

Ryan Fleming

Senior Solutions Consultant

Model N

Jeff Albright

Director, Product Management, Life Sciences Commercial Solutions